Comment on 'Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product' by Sabroe and Sabers

Acta Neurologica Scandinavica

Volumn 118, Issue 2, 2008, Pages 136-137

  Fuglsang, A ^a   Holte, o ^a   Madsen, S ^a  

^a Norwegian Medicines Agency   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ADDITIVE; GENERIC DRUG; LAMOTRIGINE; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRESS SYNDROME; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG PURITY; DRUG SAFETY; DRUG SUBSTITUTION; EPILEPSY; HUMAN; LETTER; RECOMMENDED DRUG DOSE; NOTE; PRACTICE GUIDELINE; SAFETY;

ANTICONVULSANTS; DRUGS, GENERIC; EPILEPSY; HUMANS; PRACTICE GUIDELINES AS TOPIC; SAFETY; TRIAZINES;

EID: 55949100496     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01048.x     Document Type: Letter

References (4)

1. SABROE TP, SABERS A. Progressive anticonvulsant hypersen-sitivity syndrome associated with change of drug product. Acta Neurol Scand 2008, in press.
2. ICH TOPIC Q3B(R). Note for guidance on impurities in new drug products CPMP/ICH/2738/99, 2003.
3. SCHAUB JE, WILLIAMSON PJ, BARNES EW, TREWBY PN. Multisystem adverse reaction to lamotrigine. Lancet 1994; 344:481.
4. DANISH MEDICINES AGENCY. Mulighed for forhøjet tilskud til epilepsipatienter med sÆrlig høj terapeutisk tÆrskel. Ugeskr Laeger 2007;169:322.